Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
Anavex Life Sciences (Nasdaq: AVXL) announced its participation in the 7th Annual Evercore ISI HealthCONx Conference 2024 in Coral Gables, FL. CEO Christopher U. Missling will engage in a fireside chat on December 4th, 2024, at 3:25pm ET. The conference brings together over 600 industry experts and leaders from more than 225 healthcare companies, covering sectors including Biotechnology, Pharma, Healthcare Distribution, Services & Technology, Life Science Tools & Diagnostics, and Healthcare Facilities.
The presentation will be available via audio webcast through Anavex's website, with a replay option available later that day. Anavex focuses on developing therapeutics for various conditions including Alzheimer's, Parkinson's, schizophrenia, and Rett syndrome.
Anavex Life Sciences (Nasdaq: AVXL) ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore ISI HealthCONx 2024 a Coral Gables, FL. Il CEO Christopher U. Missling parteciperà a una chiacchierata informale il 4 dicembre 2024, alle 15:25 ET. La conferenza riunisce oltre 600 esperti e leader del settore provenienti da più di 225 aziende sanitarie, coprendo settori tra cui Biotecnologia, Farmaceutica, Distribuzione Sanitaria, Servizi e Tecnologia, Strumenti e Diagnostica delle Scienze della Vita e Strutture Sanitarie.
La presentazione sarà disponibile tramite webcast audio attraverso il sito web di Anavex, con un'opzione di riproduzione disponibile successivamente quel giorno. Anavex si concentra sullo sviluppo di terapie per varie condizioni, tra cui Alzheimer, Parkinson, schizofrenia e sindrome di Rett.
Anavex Life Sciences (Nasdaq: AVXL) anunció su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx 2024 en Coral Gables, FL. El CEO Christopher U. Missling participará en una charla informal el 4 de diciembre de 2024, a las 3:25 p.m. ET. La conferencia reúne a más de 600 expertos y líderes de la industria de más de 225 empresas del sector salud, abarcando áreas como Biotecnología, Farmacéutica, Distribución Sanitaria, Servicios y Tecnología, Herramientas y Diagnósticos de Ciencias de la Vida, y Instalaciones de Salud.
La presentación estará disponible a través de una transmisión de audio en el sitio web de Anavex, con una opción de repetición disponible más tarde ese día. Anavex se centra en desarrollar terapias para diversas condiciones, incluyendo Alzheimer, Parkinson, esquizofrenia y síndrome de Rett.
Anavex Life Sciences (Nasdaq: AVXL)는 플로리다주 코럴 개이블스에서 열리는 제7회 연례 Evercore ISI HealthCONx 컨퍼런스 2024에 참석한다고 발표했습니다. CEO Christopher U. Missling은 2024년 12월 4일 오후 3시 25분(ET)에 화상 대화에 참여할 예정입니다. 이 컨퍼런스는 225개 이상의 의료 회사에서 온 600명 이상의 산업 전문가와 리더들을 모으며, 생명 공학, 제약, 의료 유통, 서비스 및 기술, 생명 과학 도구 및 진단, 의료 시설 등 여러 부문을 다룹니다.
발표 내용은 Anavex의 웹사이트를 통해 오디오 웹캐스트로 제공되며, 그날 나중에 재생 옵션도 제공됩니다. Anavex는 알츠하이머, 파킨슨병, 정신 분열증, 레트 증후군 등을 포함한 다양한 질병 치료제를 개발하는 데 중점을 두고 있습니다.
Anavex Life Sciences (Nasdaq: AVXL) a annoncé sa participation à la 7ème Conférence Annuelle Evercore ISI HealthCONx 2024 à Coral Gables, FL. Le PDG Christopher U. Missling participera à une discussion informelle le 4 décembre 2024 à 15h25 ET. La conférence réunit plus de 600 experts et leaders de l'industrie venus de plus de 225 entreprises du secteur de la santé, couvrant des domaines tels que la Biotechnologie, la Pharmaceutique, la Distribution de Santé, les Services et Technologie, les Outils de Sciences de la Vie et Diagnostics, ainsi que les Établissements de Santé.
La présentation sera disponible via un webcast audio sur le site d'Anavex, avec une option de rediffusion accessible plus tard dans la journée. Anavex se concentre sur le développement de thérapies pour diverses conditions, y compris Alzheimer, Parkinson, schizophrénie et syndrome de Rett.
Anavex Life Sciences (Nasdaq: AVXL) gab bekannt, dass es an der 7. jährlichen Evercore ISI HealthCONx-Konferenz 2024 in Coral Gables, FL, teilnimmt. CEO Christopher U. Missling wird am 4. Dezember 2024 um 15:25 Uhr ET an einem informellen Gespräch teilnehmen. Die Konferenz bringt über 600 Branchenexperten und Führungskräfte aus mehr als 225 Gesundheitsunternehmen zusammen, die Bereiche wie Biotechnologie, Pharma, Gesundheitsvertrieb, Dienstleistungen und Technologie, Lebenswissenschaften Werkzeuge & Diagnostik sowie Gesundheitseinrichtungen abdecken.
Die Präsentation wird über einen Audio-Webcast auf der Website von Anavex verfügbar sein, mit einer Wiederholungsmöglichkeit, die später an diesem Tag zur Verfügung steht. Anavex konzentriert sich darauf, Therapeutika für verschiedene Erkrankungen wie Alzheimer, Parkinson, Schizophrenie und das Rett-Syndrom zu entwickeln.
- None.
- None.
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat being held December 4th, 2024 at 3:25pm ET at the 7th Annual Evercore ISI HealthCONx Conference 2024 in Coral Gables, FL.
This year’s conference features over 600 industry experts and corporate leaders from more than 225 leading healthcare companies. The participating public and private companies will cover all the major healthcare verticals over the entirety of the event, including Biotechnology, Major/Specialty Pharma, Healthcare Distribution, Services & Technology, Life Science Tools & Diagnostics, and Healthcare Facilities & Managed Care.1
An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
1 https://investors.evercore.com/news-releases/news-release-details/evercore-hosts-7th-annual-healthconx-conference-dec-3-5-2024
FAQ
When is Anavex (AVXL) presenting at the Evercore ISI HealthCONx Conference 2024?
How can investors access Anavex's (AVXL) presentation at the HealthCONx Conference?
What therapeutic areas does Anavex (AVXL) focus on developing treatments for?
How many companies are participating in the 2024 Evercore ISI HealthCONx Conference where AVXL is presenting?
